Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Nilvad Trial posted a history of the trial update in early March which ClinicalTrials.gov published today. Near as I can tell, all it indicates is that the Nilvad Trial has been completed.
https://clinicaltrials.gov/archive/NCT02017340/2017_03_05/changes
Still thirsting for results, but at least it's a sign of life!
My reaction is that you are not being realistic. Roskamp has done three mouse studies, peer reviewed and published, in which the peer reviewers, apparently impressed with the results, recommended additional studies.
The reaction by other medical researchers? ZILCH! No one believes it! Not even the support groups for AD, Hashimoto's Thyroiditis, or Multiple Sclerosis, which were the object of the three studies.
Again, some success with Nilvad and AD, may lead to the recognition that Anatabine desperately needs.
Agree with you 110% that anatabine is (may be) much more than Alzheimer's. Even Dr Mullan has said repeatedly that Alzheimer's research is way too expensive and takes years for a proper study.
However, right now anatabine is NOTHING, ZERO, and has been totally ignored, like a crazy relative in the attic. If some success with Nilvadipine and AD can get some serious attention for anatabine, then I say hooray for Nilvad/A'bine.
Archer has already developed ARC031 which is the isomer of Nilvadipine which produces the anti-Alzheimer's results.
Dr Mullan has repeatedly said that the treatment for Alzheimer's will probably be a cocktail of more than one drug. It would be great if anatabine was part of that cocktail.
If a study gets done this year, it should be the one on people with mild to moderate psoriasis. Until the "Mechanism of Action" on human beings is demonstrated, no one is listening to the wondrous claims of what anatabine can do. It has been my experience that when one attempts to explain anatabine's potential as expressed in the use patent, to medical or non medical persons, their eyes begin to glaze over with disbelief in a "I've heard all this before" sort of way. We need incontrovertible proof before anyone pays any attention to anatabine.
"Mullan clearly said the amyloid hypothesis is a bust. ...25 years of research down the drain? Basically a total waste."
HE has repeated that same message recently in the 4/2/17 newspaper interview and again in the 5 minute Youtube video. IN MY OPINION, that message was aimed at BIG PHARMA, when Mullan knew full well that having completed The Nilvad Study, he is at least 3 years ahead of them in finding that evasive "breakthrough" in the treatment of Alzheimer's.
I sympathize with your feeling that "it appears to have been a bust.", since we have been waiting so long for the study results. However, Roskamp and Mullan have been so active lately, where previously we rarely heard from them, that I suspect it is because they are about to receive worldwide attention for their Nilvad work.
Will that benefit the stockholders of the former Rock Creek Pharmaceutical? I have no idea, but have all fingers crossed!!!!!
Here are a couple of older papers which highlight Roskamp’s hypothesis that three factors combine to cause Alzheimer’s Disease, and that both nilvadipine and anatabine can reduce, and maybe block all three factors.
The first is the discovery, with nilvadipine, that all three factors are downstream from the Syk enzyme (spleen tyrosine kinase). Theoretically, targeting Syk should impact all three factors implicated in AD.
http://health.heraldtribune.com/2014/10/28/sarasota-scientists-excited-potential-alzheimers-breakthrough/
The second is a peer-reviewed and published study which focuses on anatabine’s potential to impact the three factors believed to be responsible for causing AD, and is clearly explained in the SUMMARY on page 1.
http://health.heraldtribune.com/2014/10/28/sarasota-scientists-excited-potential-alzheimers-breakthrough/
Will it be good for RCPIQ shareholders?
No one who posts on this board knows the answer to that question, but I did address that question in post #27884. Should Nilvadipine turn out to be at least a modest breakthrough in the effort to stop Alzheimer's in its tracks, it would make Roskamp the center of worldwide attention. Dr. Mullan is in charge, under the NILVAD STUDY, to bring an Alzheimer's supressing medication to market, and most here believe that anatabine can help in that effort.
At the very least, success with Nilvad should at least bring increased attention to anatabine as a safe anti-inflammatory.
Couldn't help but notice that some here got the wrong message from the new 5 minute video by Dr. Mullan that I posted a week ago. Yes, he did say that the amyloid hypothesis, which said that the accumulation of amyloid in the brain was the sole cause of Alzheimer's, turned out to be false, and was was pursued needlessly for 25 years. But that was not the case with Roskamp!
If you take a look at the attached link you will see that 2 1/2 years ago Roskamp was pursuing what it believes are the combined three causes leading to AD. And, during the past 2 1/2 years they have completed "The Nilvad Study", and should be reporting the results any time now!
Of course we are hoping those results are positive!
http://www.alzheimersweekly.com/2014/11/nilvadipine-stirs-excitement-as.html
New 5 minute video by Dr. Michael Mullan on Alzheimer's Disease.
seek
Since we are dealing only in "opinion" as we have no hard info, I have been thinking lately that this may be proceeding as planned.
It has been over 6 months since RC went the Chapter 7 route, and nothing has happened yet. Perhaps, Chapter 7 was a way of stemming the share bleeding, and was agreed to by all parties involved, (except shareholders). The plan may have been to hold everything in limbo until the NILVAD results are released. A breakthrough, no matter how small, would give Roskamp Institute and Archer Pharmaceuticle incredible worldwide attention as having beaten WORLDWIDE BIG PHARMA to the Alzheimer's Disease breakthrough.
This would bring millions of eyes to the Roskamp website I posted earlier, showing the world how Roskamp Institute is leading the world in the anti-inflammatory approach to disease treatment, and the "inflammaging" (inflammation aging) theory of aging.
And who has the best, low side effects anti-inflammatory?
YES! Jonnie Williams with his WORLD PATENT.
At that point, Rock Creek would have no trouble getting all the money needed to restart (with all parties agreed) including shareholders.
Here is a link to the updated Roskamp Institute website. A lot of interesting stuff about The Institute, especially under the heading "What We Do".
http://www.roskampinstitute.org/
If I were an optimist, I would assume the website do-over was to introduce the world to what Roskamp Institute "is" and "does", after Dr. Mullan reports the results of the NILVAD Study, hopefully with the news that at least a partial breakthrough in slowing or stopping the progression of Alzheimer's has been achieved.
Is it possible to remove a message as I inadvertently posted a link to my e-mail account in message #28081?
Also take a look at the new Roskamp Institute. Looks like they may be getting ready for the NILVAD STUDY results release!
Sure hope so!!!!
Sorry about that. Click on Roskamp Institute e-mail!
Does anyone know if Jonnie, as applicant for the World Patent, retains any legal standing in this situation, or is he out in the cold like the rest of us?
Looks like Nuke John has "flown the coop". He hasn't posted in a long time, and is no longer monitoring the board. More than once he has brought up the subject of selling rights to the patent one disease at a time. Don't know if that would be possible since once you introduce anatabine to the body it will prevent or treat everything its MOA can treat. Perhaps, if it were sold to be added to an existing drug with that drug advertised "with anatabine". For instance "Lipitor w/anatabine".
Three business days came and went without my hearing a word from the New York Times Op Ed, so a e-mailed a two page explanation of anatabine to Carl Bernstein, keying it to the untold story of one Jonnie Williams, non-scientist, who may have discovered a Nobel worthy treatment for a couple of hundred medical conditions. Hopefully, his natural investigative reporter instincts and curiosity will be aroused!
As I troll The internet and pick up story after story relevant to NFKB, chronic inflammation, the newly discovered biomarker GlycA for cardiac event risk, the huge Japanese study of the elderly (55 to 105), etc., they all cry out for Dr. Mullan's statement in the Rock Creek ad in the biopharmadealmakersnature publication (June 2016): "Much of the scientific excitement about this drug (anatabine) derives from the potentially far-reaching clinical relevance of its mechanism of action, implicated as it is in a wide range of inflammatory and immunological conditions".
"scientific excitement" ???? With RCPIQ at $.0012 ????
"knuts....Well we could try to make it happen."
As well as e-mailing 22 of the 23 SENATORS on the Senate Health etc. Committee mentioned in a previous message, I sent a follow-up e-mail to Senators Rand Paul and Elizabeth Warren, both on that Senate Committee, and mailed a folio of material to Senator Bernie Sanders who is also on the Senate Health Committee.
A couple of weeks ago I hand delivered the same folio of material to the local office of Richie Neal, Senior Democrat on the Ways and Means Committee, where I fully explained it to one of his staff members who seemed glazzy eyed until I showed her the 2 Congressionaly Directed Awards issued to Dr. Fiona Crawford for studies of anatabine for Veterans suffering from Gulf War Illness and mTBI. She said she to was a veteran and was much more interested from then on.
This week Senator Elizabeth Warren made a 10:30 AM presentation and took questions here at her local office ( moved to a nearby theater to accomodate the hundreds who showed up). I went there with the same folio and was able to give it to one of the people travelling with her. Questions went to persons chosen by number given to attendees as they entered the theater. No.s 75 and 76 got to ask their question. I had # 77!
Yesterday I sent an e-mail to The New York Times Op Ed tying anatabine to the current battle over The Affordable Care Act. If I don't hear from them in three days (their timeline), I'll send it to USA Today.
I'm trying to make it happen!!!
The "perfect storm" for anatabine went down the drain with Trump's choice of Scott Gottlieb to head the FDA, a win for BIG PHARMA, as he was their choice, and is a loss for RCPIQ, since he will likely continue the current drug approval process, prove safety and efficacy first, which is incredibly expensive and lengthy.
Jim O'Neill's "just prove safety, then let the marketplace and doctors determine efficacy" was ideal for anatabine.
Dare we hope for a “perfect storm” in anatabine?
The Trump administration, in the hope of lowering drug prices, is considering letting drugs go to market as soon as they are proven safe. Anatabine, under those circumstances, could easily go to market as an anti-inflammatory, having been taken by at least several hundred thousand individuals, including myself, during the 3 years it was available as Anatabloc, as well as the standard safety testing completed by Rock Creek.
NukeJohn in InvestorsHub/RCPI message #27546 said “If the company is forced into bankruptcy, I would imagine Dr. Mullan will be forced to sell the patents to the highest bidder”. “Perhaps the best approach would be to sell the rights to the patents one illness at a time to individual big pharmas”.
Here’s hoping that this is how the bankruptcy will turn out! Certainly this is what the major creditors and stockholders should be demanding!
UPDATE:
Fred Couples won The Chubb Classic alone in 1st place 16 strokes below par, 3 strokes below #2, and 5 strokes below 3 golfers tied for 3rd place. He takes home $240,000.
UTTERLY AWESOME!!!!!
Fred Couples finished day/2 of this weekend's Champions golf match tied for 2nd place with one other golfer, and they are one stroke behind the leader.
Here's hoping he is still on Anatabloc!!!!
Just e-mailed the following message to 22 of the 23 members of the Senate Committee on Health, Education, Labor and Pensions.
Hoping to stir some interest.
"The purpose of this contact is to alert the Senator to a little known possible medical breakthrough which could dramatically lower the demand for medical intervention, and thereby lower the overall cost of the national medical expense burden.
I urge you not to dismiss this as a crank letter, much as I did when I first heard of the breakthrough five years ago. The premise of a “breakthrough” is supported by three peer reviewed and published pre-clinical studies in models of multiple sclerosis, Alzheimer’s disease and autoimmune thyroiditis. Each concluded that study results called for further study.
The alkaloid used in these studies was anatabine citrate. On 23 Mar 2011 an International Patent Filing was made https://www.google.com/patents/WO2011119722A2?cl=en entitled “Use of Anatabine to Treat Inflammation and Methods of Synthisizing Anatabine”. The patent application goes on to explain how anatabine accesses every cell in the body, and safely modulates aberrant inflammation, which in turn can treat or prevent well over 200 inflammatory conditions or diseases.
Much of what is known and proven about this ability of anatabine citrate was discovered
by the team of doctors and clinicians at The Roskamp Institute in Sarasota FL under the leadership of Drs Michael Mullan and Fiona Crawford. It was they that produced the three peer reviewed and published pre-clinical studies. Dr. Mullan is also the Exploitation and Scientific Director of the NILVAD Project, a 500 patient, multi-year phase 3 study of the ability of Nilvadipine to treat mild to moderate Alzheimer’s, which is currently concluding in Europe. Dr. Crawford has been working closely with the Veterans Association for many years in studies of Gulf War Illness (GWI), Post Traumatic Stress Disorder (PTSD), Traumatic Brain Injury (TBI) and Mild Repetitive Brain Injury (MRBI), and has recently received funding from a congressional program to test veterans with GWI and MRBI using anatabine, and measuring its ability to reduce their symptoms.
The medical and pharmaceutical industries have refrained from any mention of the patent claims or study results, perhaps because an inexpensive, safe and effective anti-inflammatory would reek havoc on the current system, significantly reducing demand for medical treatment and pharmacology.
It is incumbent on members of The Senate Committee on Health, Education, Labor and Pensions to interview both Dr. Mullen and Dr. Crawford in order to determine the potential for lowering medical costs through the use of anatabine as an inexpensive, safe and effective anti-inflammatory!"
bhp1rtp
Delighted to see you are still with us, and still coming up with timely articles which tease us with the thought of "what could anatabine citrate do in this situation".
Lilly's work mentions 6 disease states, 2 of which Alz's and multiple sclerosis have been shown to be beneficially affected by anatabine citrate in published, peer reviewed articles of pre-clinical studies done by Roskamp Institute.
I continue to believe that the bankruptcy court will be properly informed of the potential of the Rock Creek IP, by both JW and the loan holders.
Surprised no one mentioned that Fred Couples came in 2nd at the Champions Championship golf match in Hawaii last week with 14 under par. Residual effects of Anatabloc no doubt. He received $165,000 for that performance.
This study from Japan seem to say it all:
http://www.ebiomedicine.com/article/S2352-3964(15)30081-5/fulltext
The discussion summary concludes with the following paragraph:
“Despite these limitations, our study showed that over a very wide age range from 45 to 115 years, including unprecedentedly large numbers of the extremely old, inflammation is an important driver of ageing that might be amenable to future pharmacological intervention. Accordingly, designing novel, safe anti-inflammatory or immune-modulating medication has major potential to improve healthy lifespan.”
Why oh why has the three year availability over the counter of anatabine citrate (Anatabloc), taken safely by about 500,000 people been totally ignored?
I fully share your plan on not going away, but am holding off on the "scam" theory for now. I still do not understand why anatabine citrate's ability to safely reduce inflammation is not the biggest news in medical progress.
Dr. Michael Mullin summed it all up brilliantly in the full page ad aimed at potential investors. What, if anything, was incorrect in that ad?
Yet no comment, no response, no criticism, no correction from anyone on what to me sounds like a huge step forward for billions of people to feel better on a daily basis!!!!!
Was hoping we would get the Nilvad trial results before any attempt to sell the anatabine IP. Should Nilvadipine prove to be the first significant breakthrough towards a treatment for AD, and Dr. Mullan the lead person to commercialize that potential, it could get some extra attention for anatabine as he is the lead discoverer on that as well.
Found the following at sec.gov:
"Stockholders do not have to be notified of the Chapter 7 case because they generally don't receive anything in return for their investment. But, in the unlikely event that creditors are paid in full, stockholders will be notified and given an opportunity to file claims."
At the risk of repeating myself, the creditors who have an $85 million claim against any available assets are likely far more determined to squeeze value out of the IP (intellectual property) than beleaguered ex-stockholders. Mullan and co. gave full exposure to anatabine's anti-inflammatory potential, but the media, the markets, and the medical industry paid no attention.
Am hoping we eventually find out why anatabine's seemlngly safe and "novel anti-inflammatory pathway" was not found to be an outstanding medical discovery!!!
The long and short of it would seem to be assets vs liabilities. Since we are looking at $35,000 in assets and $85 million in liabilities, it would seem to be a grim outlook for stockholders.
It all boils down as to whether or not the patents (intellectual property)is included in the assets, and what is the true value of those patents, if indeed they are in the asset column.
Since the creditors are in the hole for $85 million, it seems logical that they would move heaven and earth to see to it that the patents reflect their true long-term value. What would Donald Trump do if he were one of the creditors?
The following link is to an Oct. 2016 AARP Bulletin interview of Rudolph Tanzi, a Harvard Univ. neuroscientist and one of the world’s leading researchers on Alzheimer’s.
He says you can have the plaques and tangles and never have AD, but if you develop INFLAMMATION it kick starts Alzheimer’s Disease.
If that’s true as I believe it to be, why hasn’t the world been all excited about what we know to be a safe and effective anti -inflammatory?????????
http://www.aarp.org/health/brain-health/info-2016/alzheimers-cure-research-drugs-hd.html
Those were the "Good Old Days".
Buddhahead Saturday, 05/10/14 01:59:57 PM
Re: None
Post # ?of 18897 ?
Chronic Inflammation NF-kB meta searches: Over 2 million hits of articles, research, dissertations, papers, conferences, and websites on the subject. The elephant in the room is: reducing chronic inflammation by targeting NF-kB. Chronic inflamation is implicated in autoimmune disorders, chronic diseases, heart diseases and cancers. Only in the last couple of years, there has been an explosion in the information available about the chronic inflammation NF-kB connection. Prevention appears to be the keyword for today's focus.
The biggest investments/research for pharmaceuticals appears to be in cancer, heart, and Alzheimers/dementia related research. Chronic inflammation is implicated in all three areas. Chronic inflammatory disease is the new kid on the block and researchers all over the globe are investigating it's complex interactions, therapies, and possibilities. Almost all researchers are focused on the NF-kB link and there must be a reason.
I think STSI and Rosenkamp are at the 'sweetspot' of this arena. Like the history of Alexander Fleming's discovery of penicillin, the finding of anti-inflammatory solutions will probably be the next great thing in medicine.
Link needs to be corrected to read "@calicolabs.com"
You say, "Not junk science". I assume that is just an opinion since no credible entity has recognized the significance of any of Roskamp's findings, including the significance of blocking SYK to stop the progression of Alzheimer's.
5 years now since the anatabine USE PATENT application, and we still don't know if we are looking at a Nobel worthy discovery or junk science!
VOTE NOW!
If as you said,
"The main difference between Chapter 7 and Chapter 11 bankruptcy is that under a Chapter 7 bankruptcy filing, the debtor's assets are sold off to pay the lenders (creditors)", then we may finally find out what the anatabine citrate intellectual property (IP) is worth.
To the bitter end I have been thoroughly convinced that Cox and Fassell were right, since I took Anatabloc for 3 years and was delighted with the results it provided an 80 year old.
seek
Just getting around to responding to your post "Interesting Research" from a month ago. It reminded me of a Jonnie Williams patent from the good old days.
http://www.freepatentsonline.com/result.html?p=1&edit_alert=&srch=xprtsrch&query_txt=6350479%0D%0A&uspat=on&date_range=all&stemming=on&sort=relevance&search=Search